ProShare Advisors LLC Makes New $137,000 Investment in UroGen Pharma Ltd. (NASDAQ:URGN)

ProShare Advisors LLC bought a new stake in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,895 shares of the company’s stock, valued at approximately $137,000. ProShare Advisors LLC owned approximately 0.05% of UroGen Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the business. SG Americas Securities LLC grew its stake in shares of UroGen Pharma by 44.1% in the 4th quarter. SG Americas Securities LLC now owns 20,269 shares of the company’s stock worth $216,000 after buying an additional 6,207 shares during the last quarter. Rhumbline Advisers boosted its holdings in UroGen Pharma by 2.8% in the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock worth $546,000 after acquiring an additional 1,402 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of UroGen Pharma by 7.3% in the fourth quarter. Bank of New York Mellon Corp now owns 93,997 shares of the company’s stock worth $1,001,000 after acquiring an additional 6,430 shares during the last quarter. ARK Investment Management LLC increased its holdings in shares of UroGen Pharma by 15.2% during the fourth quarter. ARK Investment Management LLC now owns 140,148 shares of the company’s stock valued at $1,493,000 after acquiring an additional 18,514 shares in the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in shares of UroGen Pharma during the fourth quarter valued at $126,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

URGN has been the topic of several recent analyst reports. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday, May 8th. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 22nd. Guggenheim cut their target price on UroGen Pharma from $40.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 23rd. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. Finally, Scotiabank initiated coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price target on the stock. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.43.

UroGen Pharma Price Performance

Shares of URGN opened at $4.84 on Tuesday. The firm has a fifty day simple moving average of $9.12 and a two-hundred day simple moving average of $10.32. The firm has a market cap of $223.16 million, a PE ratio of -1.54 and a beta of 0.66. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 1-year low of $3.42 and a 1-year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. On average, equities analysts anticipate that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.